Know Cancer

or
forgot password

Whole Exon Sequencing of Down Syndrome Acute Myeloid Leukemia


N/A
N/A
3 Years
Open (Enrolling)
Both
Leukemia

Thank you

Trial Information

Whole Exon Sequencing of Down Syndrome Acute Myeloid Leukemia


OBJECTIVES:

- To identify new genetic abnormalities associated with acute myeloid leukemia (AML) in
patients with Down syndrome through whole-genome sequencing.

OUTLINE: This is a multicenter study.

Extracted DNA and RNA from cryopreserved specimens are analyzed for genomic sequencing, gene
mutation, and microarray analysis.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Down syndrome children diagnosed with acute myeloid leukemia (AML) or myelodysplastic
syndromes (MDS)

- Clinical samples from patients enrolled on the Children's Oncology Group (COG)
AAML0431 phase III clinical trial, and from the Children's Hospital of Michigan Cell
Bank

- Diagnostic blast samples and matched remission samples

PATIENT CHARACTERISTICS:

- Not specified

PRIOR CONCURRENT THERAPY:

- Not specified

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Identification of unique mutations through whole-genome sequencing

Safety Issue:

No

Principal Investigator

Jeffrey Taub, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Children's Hospital of Michigan

Authority:

United States: Federal Government

Study ID:

CDR0000721624

NCT ID:

NCT01507441

Start Date:

February 2012

Completion Date:

Related Keywords:

  • Leukemia
  • childhood myelodysplastic syndromes
  • childhood acute myeloid leukemia/other myeloid malignancies
  • childhood acute megakaryocytic leukemia (M7)
  • Down Syndrome
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location